Skip to main content
. Author manuscript; available in PMC: 2017 Dec 21.
Published in final edited form as: Cancer. 2017 Jul 14;123(22):4430–4439. doi: 10.1002/cncr.30883

Figure 2.

Figure 2

(A) Event-free survival (EFS) and (B) overall survival (OS) for patients treated with idarubicin and cytarabine with clofarabine (CIA), idarubicin and cytarabine with fludarabine (FIA), and an idarubicin and cytarabine (IA) historical cohort.